Showing 521-530 of 839 results for "".
- 2022 President Robert E. Wiggins Jr., MD, MPH Takes the Academy’s Reinshttps://modernod.com/news/2022-president-robert-e-wiggins-jr-md-mph-takes-the-academys-reins/2480585/Medicine is a constantly developing industry—just ask 2022 Academy President Robert E. Wiggins Jr., MD, MPH. When his practice was acquired in the 1990s, Dr. Wiggins returned to school and obtained a masters degree in health care administration, turning Asheville Eye Associa
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- Kriya Therapeutics Appoints Theresa Heah, MD, as Chief Medical Officer and President of Kriya Ophthalmologyhttps://modernod.com/news/kriya-therapeutics-appoints-theresa-heah-md-as-chief-medical-officer-and-president-of-kriya-ophthalmology/2480354/Kriya Therapeutics announced the appointment of Theresa Heah, MD, MBA, as Chief Medical Officer and President of Kriya’s newly launched ophthalmology division, Kriya Ophthalmology. Dr Heah will be responsible for advancing Kriya’s current pipeline of ophthalmology gene therapies and c
- Eric D. Donnenfeld, MD, of OCLI Vision Named America’s Best Eye Doctor by Newsweekhttps://modernod.com/news/eric-d-donnenfeld-md-of-ocli-vision-named-americas-best-eye-doctor-by-newsweek/2479447/Eric D. Donnenfeld, MD has been named “America’s Best Eye Doctor 2021” by Newsweek. Dr. Donnenfeld ranks first out of 150 ophthalmologists with a near perfect score for quality of care, continuity of care, and the quality of the technology used in his practice. Dr. Donnenfeld
- Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-appoints-professor-shigeru-kinoshita-md-phd-to-its-medical-advisory-board/2479369/Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. Professor Kinoshita is the inventor of Aurion Biotech’s lead candidate, cell therapy for
- Ocuphire Announces Appointment of Jay S. Pepose, MD, PhD, to Its Board of Directorshttps://modernod.com/news/ocuphire-announces-appointment-of-jay-s-pepose-md-phd-to-its-board-of-directors/2479272/Ocuphire Pharma announced the appointment of Jay S. Pepose, MD, PhD, to its Board of Directors. Concurrent to Dr. Pepose’s appointment at Ocuphire’s annual shareholder meeting on June 7, Alan Meyer, MBA, retired from his role on the Board of Directors, having served since April 2018. “We a
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’
- Lexitas Announces George N. Magrath, MD, MBA Assumes Role of Chief Executive Officerhttps://modernod.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/George N. Magrath, MD, MBA, MS, has been named CEO of Lexitas Pharma Services. Chad Ice will transition from the role as CEO to President with a focus on strategic growth initiatives as well as the expansion of the Lexitas Board of Directors. These changes became effective February 1, 2021. <
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela